In April 2022, the French Health Products Agency (ANSM) reported the case of a 66-year-old patient who suffered cardio-respiratory arrest after receiving several injections of trimebutine via a central venous catheter (1). In France, trimebutine has been marketed since the 1970s as a "regulator of gastrointestinal motility", with numerous "indications" ranging from oesophagitis, barium enema, biliary dyskinesia, and gastrointestinal (Gl) endoscopy to postoperative restoration of Gl motility, and all from birth onwards (2). Just one adverse effect was mentioned with the injectable form: "occasional faintness"(2).
展开▼
